Adam Chill Net Worth

Adam Chill biography

Adam J. Chill serves as Independent Director of the Company. Mr. Chill is the President of and a Portfolio Manager at Kingsbrook Partners LP, an alternative asset management firm he co-founded in March 2009. From February 2001 to March 2009, Mr. Chill was a Portfolio Manager and Managing Director at Highbridge Capital Management, LLC, an alternative asset management firm owned by J.P. Morgan Asset Management. At Highbridge, Mr. Chill was responsible for structuring, negotiating and monitoring Highbridge’s portfolio of structured investments in public and private companies worldwide. From April 2000 to February 2001, Mr. Chill worked at Angelo, Gordon & Co., an alternative asset management firm. From October 1992 to April 2000, Mr. Chill was a corporate attorney specializing in securities and mergers and acquisitions at Stroock & Stroock & Lavan LLP. Mr. Chill serves as Vice President and a member of the Executive Committee of the American Friends of Shalva, the Association for Mentally and Physically Challenged Children in Israel. Mr. Chill received his B.A., magna cum laude, from Yeshiva University and his J.D. from Columbia University School of Law, where he was a Harlan Fiske Stone Scholar. Based on Mr. Chill’s extensive investment experience and knowledge of the biotechnology industry, the Board of Directors believes that Mr. Chill has the appropriate set of skills to serve as a member of the Board.

What is the salary of Adam Chill?

As the Independent Director of Mustang Bio Inc, the total compensation of Adam Chill at Mustang Bio Inc is $110,000. There are 4 executives at Mustang Bio Inc getting paid more, with Dr. Manuel Litchman having the highest compensation of $606,871.

How old is Adam Chill?

Adam Chill is 52, he's been the Independent Director of Mustang Bio Inc since 2017. There are 9 older and no younger executives at Mustang Bio Inc. The oldest executive at Mustang Bio Inc is Dr. Manuel Litchman, 67, who is the Pres, CEO & Director.

Insiders trading at Mustang Bio Inc

Over the last 7 years, insiders at Mustang Bio Inc have traded over $122,072 worth of Mustang Bio Inc stock and bought 951,208 units worth $2,853,591 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss oraz Manuel Md Litchman. On average, Mustang Bio Inc executives and independent directors trade stock every 89 days with the average trade being worth of $15,504. The most recent stock trade was executed by Manuel Md Litchman on 18 March 2022, trading 10,000 units of MBIO stock currently worth $6,300.

What does Mustang Bio Inc do?

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.

Mustang Bio Inc executives and stock owners

Mustang Bio Inc executives and other stock owners filed with the SEC include:

• Dr. Manuel Litchman,
  Pres, CEO & Director
• Manuel Litchman,
  President, Chief Executive Officer, Director
• Brian Achenbach,
  Senior Vice President - Finance, Corporate Controller
• Brian K. Achenbach M.B.A.,
  Sr. VP of Fin. & Corp. Controller
• Adam Chill,
  Independent Director
• Michael Weiss,
  Executive Chairman of the Board
• Michael Zelefsky,
  Independent Director
• Neil Herskowitz,
  Independent Director
• Lindsay Rosenwald,
  Director
• Michael S. Weiss Esq.,
  Exec. Chairman
• Robyn M. Hunter,
  Corp. Sec.
• Dr. Bruce Dezube M.D.,
  Sr. VP & Head of Clinical Devel.
• Scott Smith M.B.A.,
  Exec. Director and Head of Alliance & Program Management
• Lynn E. Bayless,
  Head of Regulatory Affairs
• Debra Manning SPHR,
  VP of HR
• Matthew Wein J.D.,
  VP & Gen. Counsel
• Dr. Knut Niss,
  Chief Technology Officer
• Biotech, Inc. Fortress,
  10% owner